Want to see GRAL full AI Analyst Report?
GRAL Stock Chart & Stats
$67.84
-$0.05(-0.07%)
At close: 4:00 PM EDT
$67.84
-$0.05(-0.07%)
Day’s Range― - ―
52-Week Range$29.95 - $118.84
Previous CloseN/A
Volume220.30K
Average Volume (3M)539.76K
Market Cap
$3.05B
Enterprise Value$1.33K
Total Cash (Recent Filing)$823.11M
Total Debt (Recent Filing)$51.03M
Price to Earnings (P/E)―
Beta2.59
Next Earnings
Aug 05, 2026EPS Estimate
-2.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.37
Shares Outstanding42,916,590
10 Day Avg. Volume438,988
30 Day Avg. Volume539,764
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$69.25Price Target Upside2.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-10.33
Revenue Forecast (FY)$178.72M
Bulls Say, Bears Say
Bulls Say
Robust Volume & Revenue GrowthSustained test volume growth and rising screening revenue indicate durable commercial adoption and expanding clinician/patient utilization. Higher volumes drive fixed-cost leverage, support unit-cost improvements and underpin scalable revenue growth as integrations and new prescribers broaden distribution over multiple quarters.
Low Leverage & Strong LiquidityA very low debt load gives the company financial flexibility to fund commercialization and regulatory milestones without near-term solvency pressure. Coupled with the reported cash balance, low leverage reduces refinancing risk and supports multi-quarter investment in sales, evidence generation, and integration projects.
Regulatory Acceptance & Large Evidence BasePMA acceptance plus a large dataset (PATHFINDER 2 and NHS-Galleri) and upcoming ASCO readouts materially strengthen the clinical and regulatory case. This durable evidence trajectory can enable coverage, guideline inclusion and broader provider confidence over months to years, supporting long-term market access.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow of roughly -$291M TTM shows the company still requires substantial cash to fund operations. Even with improved trends, sustained negative FCF increases dependency on existing liquidity or financings and pressures the timeline to reach sustainable unit economics.
NHS‑Galleri Primary Endpoint MissA null combined endpoint creates lasting questions among providers and payers about clinical impact and utility. That outcome increases the burden of evidence required for adoption and coverage, can slow payer decisions and necessitates detailed data presentations to restore confidence across health systems and employers.
ASP Pressure & Pricing MixDeclining average selling price from population pricing and discounts exerts structural pressure on gross margins. Even with fixed-cost leverage, prolonged ASP erosion reduces per-test economics and could negate volume-driven margin improvements absent sustained cost reductions or favorable payer reimbursements.
GRAIL Inc News
GRAL FAQ
What was Grail Inc’s price range in the past 12 months?
Grail Inc lowest stock price was $29.95 and its highest was $118.84 in the past 12 months.
What is Grail Inc’s market cap?
Grail Inc’s market cap is $3.05B.
When is Grail Inc’s upcoming earnings report date?
Grail Inc’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were Grail Inc’s earnings last quarter?
Grail Inc released its earnings results on May 05, 2026. The company reported -$2.29 earnings per share for the quarter, beating the consensus estimate of -$2.763 by $0.473.
Is Grail Inc overvalued?
According to Wall Street analysts Grail Inc’s price is currently Undervalued.
Does Grail Inc pay dividends?
Grail Inc does not currently pay dividends.
What is Grail Inc’s EPS estimate?
Grail Inc’s EPS estimate is -2.66.
How many shares outstanding does Grail Inc have?
Grail Inc has 42,916,590 shares outstanding.
What happened to Grail Inc’s price movement after its last earnings report?
Grail Inc reported an EPS of -$2.29 in its last earnings report, beating expectations of -$2.763. Following the earnings report the stock price went up 15.349%.
Which hedge fund is a major shareholder of Grail Inc?
Currently, no hedge funds are holding shares in GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$69.25 (2.08% Upside)
$69.25 (2.08% Upside)
Blogger Sentiment
Bullish
GRAL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $91.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
70.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.55%
Trailing 12-Months
Company Description
Grail Inc
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful clinical and regulatory progress: test volumes grew 50% YoY, screening revenue rose 37% YoY, adjusted gross profit improved 38% YoY, PMA was accepted, and large trial datasets and upcoming ASCO readouts support the evidence base. At the same time, the NHS-Galleri primary combined endpoint was not met, ASP pressure and continued operating losses persist, media scrutiny and competitive activity create near-term headwinds, and regulatory/timing uncertainties (including possible FDA AdCom and CMS coverage) remain. Overall, positives around volume growth, margins improvement, cash runway, partnerships and regulatory progress outweigh the challenges, but the company still faces execution and perception risks that will need to be addressed in coming quarters.View all GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$69.25
▲(2.08% Upside)
Technical Analysis
Ownership Overview
11.70% Insiders
12.49% Mutual Funds
1.17% Other Institutional Investors
58.78% Public Companies and Individual Investors